Which SSRI is Most Commonly Used in PPPD Management?
Sertraline and escitalopram are the most commonly used SSRIs in PPPD management, though the evidence base does not definitively establish superiority of one specific SSRI over others—the broader class of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are considered first-line pharmacotherapy for PPPD.
Evidence for Specific SSRIs
The literature reveals that paroxetine has been specifically studied in dizzy patients. A 2004 prospective study demonstrated that 20 mg daily of paroxetine improved subjective handicaps and depressive symptoms in patients with dizziness, particularly those with high depression scores 1. This study showed 68% of patients demonstrated clinical improvement with serotonin reuptake inhibitors 2.
However, more recent evidence from 2025 examining long-term outcomes of pharmacotherapy in PPPD patients does not specify which particular SSRI was used, referring only to "serotonergic antidepressants" as a class 3. This study demonstrated sustained improvements in Dizziness Handicap Inventory (DHI), Hospital Anxiety and Depression Scale (HADS), and Niigata PPPD Questionnaire (NPQ) scores from 3 months through 3 years of treatment, with an overall adherence rate of 72.9%.
Clinical Context and Treatment Approach
PPPD is characterized by:
- Persistent dizziness, unsteadiness, or non-spinning vertigo lasting >3 months
- Exacerbation with upright posture, movement, or complex visual stimuli
- Often precipitated by acute vestibular events but symptoms persist beyond the precipitant 4
The pathophysiology involves shifts in sensory processing where visual inputs dominate over vestibular inputs, with alterations in visual-vestibular networks and limbic areas 5, 4.
Treatment Algorithm
Start with any SSRI or SNRI based on:
- Patient's psychiatric comorbidities (anxiety present in majority of PPPD patients) 2, 6
- Side effect profile tolerance
- Drug interaction considerations
Paroxetine 20 mg daily has the most direct evidence in dizzy patients 1, making it a reasonable first choice if no contraindications exist.
Monitor for:
- Initial adverse events (nausea/abdominal distension) in first 2 weeks—these typically resolve 3
- Response at 3 months (expect improvements in DHI, anxiety, and depression scores) 3
- Continued benefit through at least 1 year (responders defined as ≥18 point DHI improvement) 3
Important Caveats
Pharmacotherapy alone is insufficient. The evidence consistently emphasizes that vestibular rehabilitation therapy (VRT) is a cornerstone treatment 7. Cognitive behavioral therapy should also be considered as part of comprehensive management 5, 4.
Somatosensory hypersensitivity does not improve with SSRIs alone—HTPG (head-tilt perception gain) showed no significant improvement after pharmacotherapy, suggesting additional interventions targeting sensory reweighting are necessary 3.
High comorbidity burden: PPPD patients frequently have hypercholesterolemia (31%), migraine (26%), metabolic disorders (22%), and cervical syndrome (21%) 2. Address these concurrently.
Differential diagnosis matters: Distinguish PPPD from vestibular migraine, as the latter may respond better to migraine-specific preventive treatments like flunarizine or CGRP-targeted therapies 7.
The 72.9% adherence rate and sustained 3-year efficacy data support long-term SSRI/SNRI use in PPPD 3, but always combine with vestibular rehabilitation for optimal outcomes addressing both the functional vestibular disorder and the underlying sensory processing abnormalities.